nach oben

Medical Oncology

Erschienen in:

01.12.2011 | Original Paper

Adiponectin and breast cancer

verfasst von: Xiuping Chen, Yitao Wang

Erschienen in: Medical Oncology | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Adiponectin, an adipose tissue-derived hormone, has been studied intensively for the past decade because of its anti-inflammatory, anti-atherogenic, and anti-diabetic properties. Recent advances suggest that adiponectin also plays an important role in the development and progression of various cancers, especially obesity-related cancers. In this review, the authors focus on the potential role of adiponectin in breast cancer, an obesity- and endocrine-associated tumor. Epidemiological studies have shown that plasma adiponectin level is a risk factor for breast cancer in post-menopausal women. Adiponectin and its receptors are expressed on both breast cancer line cells and tumor tissues. Furthermore, exogenous adiponectin has exhibited therapeutic potential in animal models. Underlying mechanisms include the inhibition of cell proliferation and promotion of apoptosis, the regulation of tumorigenic-related factors, and the suppression of angiogenesis. The signaling pathways linking adiponectin with tumorigenesis might provide potential drug targets for the future. However, more convincing evidence is needed to fully elucidate the exact role of adiponectin in breast cancer, since both its beneficial effects and possible mechanisms remain controversial.

Sun Y, Xun K, Wang C, Zhao H, Bi H, Chen X, et al. Adiponectin, an unlocking adipocytokine. Cardiovasc Ther. 2009;27:59–75.PubMedCrossRef

Barb D, Pazaitou-Panayiotou K, Mantzoros CS. Adiponectin: a link between obesity and cancer. Expert Opin Investig Drugs. 2006;15:917–31.PubMedCrossRef

Barb D, Williams CJ, Neuwirth AK, Mantzoros CS. Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr. 2007;86:s858–66.PubMed

Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systematic review. Br J Cancer. 2006;94:1221–5.PubMedCrossRef

Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26:439–51.PubMedCrossRef

Mao X, Hong JY, Dong LQ. The adiponectin signaling pathway as a novel pharmacological target. Mini Rev Med Chem. 2006;6:1331–40.PubMedCrossRef

Saito K, Tobe T, Minoshima S, Asakawa S, Sumiya J, Yoda M, et al. Organization of the gene for gelatin-binding protein (GBP28). Gene. 1999;229:67–73.PubMedCrossRef

Liu M, Liu F. Transcriptional and post-translational regulation of adiponectin. Biochem J. 2010;425:41–52.CrossRef

Waki H, Yamauchi T, Kamon J, Kita S, Ito Y, Hada Y, et al. Generation of globular fragment of adiponectin by leukocyte elastase secreted by monocytic cell line THP-1. Endocrinology. 2005;146:790–6.PubMedCrossRef

10.

Beltowski J, Jamroz-Wisniewska A, Widomska S. Adiponectin and its role in cardiovascular diseases. Cardiovasc Hematol Disord Drug Targets. 2008;8:7–46.PubMedCrossRef

11.

Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003;423:762–9.PubMedCrossRef

12.

Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, Lodish HF. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci USA. 2004;101:10308–13.PubMedCrossRef

13.

Pischon T, Nothlings U, Boeing H. Obesity and cancer. Proc Nutr Soc. 2008;67:128–45.PubMedCrossRef

14.

Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y, et al. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res. 2003;9:5699–704.PubMed

15.

Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab. 2004;89:1102–7.PubMedCrossRef

16.

Chen DC, Chung YF, Yeh YT, Chaung HC, Kuo FC, Fu OY, et al. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett. 2006;237:109–14.PubMedCrossRef

17.

Hou WK, Xu YX, Yu T, Zhang L, Zhang WW, Fu CL, et al. Adipocytokines and breast cancer risk. Chin Med J (Engl). 2007;120:1592–6.

18.

Tian YF, Chu CH, Wu MH, Chang CL, Yang T, Chou YC, et al. Anthropometric measures, plasma adiponectin, and breast cancer risk. Endocr Relat Cancer. 2007;14:669–77.PubMedCrossRef

19.

Kang JH, Yu BY, Youn DS. Relationship of serum adiponectin and resistin levels with breast cancer risk. J Korean Med Sci. 2007;22:117–21.PubMedCrossRef

20.

Xu J, Meng L, Liu F, Chen L, Yu T, Zhang L, et al. The association of adiponectin, glucose and lipid metabolism with breast cancer, metastasis. Chin J Gerontol. 2008;28:2129–31.

21.

Korner A, Pazaitou-Panayiotou K, Kelesidis T, Kelesidis I, Williams CJ, Kaprara A, et al. Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab. 2007;92:1041–8.PubMedCrossRef

22.

Tworoger SS, Eliassen AH, Kelesidis T, Colditz GA, Willett WC, Mantzoros CS, et al. Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab. 2007;92:1510–6.PubMedCrossRef

23.

Maskarinec G, Woolcott C, Steude JS, Franke AA, Cooney RV. The relation of leptin and adiponectin with breast density among premenopausal women. Eur J Cancer Prev. 2010;19:55–60.PubMedCrossRef

24.

Miyatani Y, Yasui T, Uemura H, Yamada M, Matsuzaki T, Kuwahara A, et al. Associations of circulating adiponectin with estradiol and monocyte chemotactic protein-1 in postmenopausal women. Menopause. 2008;15:536–41.PubMedCrossRef

25.

Hong SC, Yoo SW, Cho GJ, Kim T, Hur JY, Park YK, et al. Correlation between estrogens and serum adipocytokines in premenopausal and postmenopausal women. Menopause. 2007;14:835–40.PubMedCrossRef

26.

Kaklamani VG, Sadim M, Hsi A, Offit K, Oddoux C, Ostrer H, et al. Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk. Cancer Res. 2008;68:3178–84.PubMedCrossRef

27.

Teras LR, Goodman M, Patel AV, Bouzyk M, Tang W, Diver WR, et al. No association between polymorphisms in LEP, LEPR, ADIPOQ, ADIPOR1, or ADIPOR2 and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2009;18:2553–7.PubMedCrossRef

28.

Karaduman M, Bilici A, Ozet A, Sengul A, Musabak U, Alomeroglu M. Tissue levels of adiponectin in breast cancer patients. Med Oncol. 2007;24:361–6.PubMedCrossRef

29.

Jarde T, Caldefie-Chezet F, Damez M, Mishellany F, Perrone D, Penault-Llorca F, et al. Adiponectin and leptin expression in primary ductal breast cancer and in adjacent healthy epithelial and myoepithelial tissue. Histopathology. 2008;53:484–7.PubMedCrossRef

30.

Takahata C, Miyoshi Y, Irahara N, Taguchi T, Tamaki Y, Noguchi S. Demonstration of adiponectin receptors 1 and 2 mRNA expression in human breast cancer cells. Cancer Lett. 2007;250:229–36.PubMedCrossRef

31.

Jarde T, Caldefie-Chezet F, Goncalves-Mendes N, Mishellany F, Buechler C, Penault-Llorca F, et al. Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies. Endocr Relat Cancer. 2009;16:1197–210.PubMedCrossRef

32.

Pfeiler G, Treeck O, Wenzel G, Goerse R, Hartmann A, Schmitz G, et al. Influence of insulin resistance on adiponectin receptor expression in breast cancer. Maturitas. 2009;63:253–6.PubMedCrossRef

33.

Dieudonne MN, Bussiere M, Dos Santos E, Leneveu MC, Giudicelli Y, Pecquery R. Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem Biophys Res Commun. 2006;345:271–9.PubMedCrossRef

34.

Dos Santos E, Benaitreau D, Dieudonne MN, Leneveu MC, Serazin V, Giudicelli Y, et al. Adiponectin mediates an antiproliferative response in human MDA-MB 231 breast cancer cells. Oncol Rep. 2008;20:971–7.PubMed

35.

Grossmann ME, Nkhata KJ, Mizuno NK, Ray A, Cleary MP. Effects of adiponectin on breast cancer cell growth and signaling. Br J Cancer. 2008;98:370–9.PubMedCrossRef

36.

Pfeiler GH, Buechler C, Neumeier M, Schaffler A, Schmitz G, Ortmann O, et al. Adiponectin effects on human breast cancer cells are dependent on 17-beta estradiol. Oncol Rep. 2008;19:787–93.PubMed

37.

Treeck O, Lattrich C, Juhasz-Boess I, Buchholz S, Pfeiler G, Ortmann O. Adiponectin differentially affects gene expression in human mammary epithelial and breast cancer cells. Br J Cancer. 2008;99:1246–50.PubMedCrossRef

38.

Nakayama S, Miyoshi Y, Ishihara H, Noguchi S. Growth-inhibitory effect of adiponectin via adiponectin receptor 1 on human breast cancer cells through inhibition of S-phase entry without inducing apoptosis. Breast Cancer Res Treat. 2008;112:405–10.PubMedCrossRef

39.

Wang Y, Lam JB, Lam KS, Liu J, Lam MC, Hoo RL, et al. Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res. 2006;66:11462–70.PubMedCrossRef

40.

Liu J, Lam JB, Chow KH, Xu A, Lam KS, Moon RT, et al. Adiponectin stimulates Wnt inhibitory factor-1 expression through epigenetic regulations involving the transcription factor specificity protein 1. Carcinogenesis. 2008;29:2195–202.PubMedCrossRef

41.

Kang JH, Lee YY, Yu BY, Yang BS, Cho KH, Yoon DK, et al. Adiponectin induces growth arrest and apoptosis of MDA-MB-231 breast cancer cell. Arch Pharm Res. 2005;28:1263–9.PubMedCrossRef

42.

Arditi JD, Venihaki M, Karalis KP, Chrousos GP. Antiproliferative effect of adiponectin on MCF7 breast cancer cells: a potential hormonal link between obesity and cancer. Horm Metab Res. 2007;39:9–13.PubMedCrossRef

43.

Ogunwobi OO, Beales IL. Globular adiponectin, acting via adiponectin receptor-1, inhibits leptin-stimulated oesophageal adenocarcinoma cell proliferation. Mol Cell Endocrinol. 2008;285:43–50.PubMedCrossRef

44.

Motoshima H, Wu X, Mahadev K, Goldstein BJ. Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun. 2004;315:264–71.PubMedCrossRef

45.

Arita Y, Kihara S, Ouchi N, Maeda K, Kuriyama H, Okamoto Y, et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation. 2002;105:2893–8.PubMedCrossRef

46.

Wang Y, Lam KS, Xu JY, Lu G, Xu LY, Cooper GJ, et al. Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem. 2005;280:18341–7.PubMedCrossRef

47.

Nkhata KJ, Ray A, Schuster TF, Grossmann ME, Cleary MP. Effects of adiponectin and leptin co-treatment on human breast cancer cell growth. Oncol Rep. 2009;21:1611–9.PubMed

48.

Grossmann ME, Ray A, Dogan S, Mizuno NK, Cleary MP. Balance of adiponectin and leptin modulates breast cancer cell growth. Cell Res. 2008;18:1154–6.PubMedCrossRef

49.

Sun Y, Chen X. Effect of adiponectin on apoptosis: pro-apoptosis or anti-apoptosis? Biofactors. 2010;36:179–86.PubMedCrossRef

50.

Horenburg S, Fischer-Posovszky P, Debatin KM, Wabitsch M. Influence of sex hormones on adiponectin expression in human adipocytes. Horm Metab Res. 2008;40:779–86.PubMedCrossRef

51.

Combs TP, Berg AH, Rajala MW, Klebanov S, Iyengar P, Jimenez-Chillaron JC, et al. Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes. 2003;52:268–76.PubMedCrossRef

52.

Asimakopoulos B, Milousis A, Gioka T, Kabouromiti G, Gianisslis G, Troussa A, et al. Serum pattern of circulating adipokines throughout the physiological menstrual cycle. Endocr J. 2009;56:425–33.PubMedCrossRef

53.

Hall N, White C, O’Sullivan AJ. The relationship between adiponectin, progesterone, and temperature across the menstrual cycle. J Endocrinol Invest. 2009;32:279–83.PubMed

54.

Kleiblova P, Springer D, Haluzik M. The influence of hormonal changes during menstrual cycle on serum adiponectin concentrations in healthy women. Physiol Res. 2006;55:661–6.PubMed

55.

Chalvatzas N, Dafopoulos K, Kosmas G, Kallitsaris A, Pournaras S, Messinis IE. Effect of ovarian hormones on serum adiponectin and resistin concentrations. Fertil Steril. 2009;91:1189–94.PubMedCrossRef

56.

Nicolini A, Carpi A, Rossi G. Cytokines in breast cancer. Cytokine Growth Factor Rev. 2006;17:325–37.PubMedCrossRef

57.

Hector J, Schwarzloh B, Goehring J, Strate TG, Hess UF, Deuretzbacher G, et al. TNF-alpha alters visfatin and adiponectin levels in human fat. Horm Metab Res. 2007;39:250–5.PubMedCrossRef

58.

Zappala G, Rechler MM. IGFBP-3, hypoxia and TNF-alpha inhibit adiponectin transcription. Biochem Biophys Res Commun. 2009;382:785–9.PubMedCrossRef

59.

Kim KY, Kim JK, Jeon JH, Yoon SR, Choi I, Yang Y. c-Jun N-terminal kinase is involved in the suppression of adiponectin expression by TNF-alpha in 3T3–L1 adipocytes. Biochem Biophys Res Commun. 2005;327:460–7.PubMedCrossRef

60.

Masaki T, Chiba S, Tatsukawa H, Yasuda T, Noguchi H, Seike M, et al. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology. 2004;40:177–84.PubMedCrossRef

61.

Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K, et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med. 2005;11:1096–103.PubMedCrossRef

62.

Tomizawa A, Hattori Y, Kasai K. Induction of gene expression in response to globular adiponectin in vascular endothelial cells. Life Sci. 2009;85:457–61.PubMedCrossRef

63.

Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116:1784–92.PubMedCrossRef

64.

Vona-Davis L, Rose DP. Angiogenesis, adipokines and breast cancer. Cytokine Growth Factor Rev. 2009;20:193–201.PubMedCrossRef

65.

Ouchi N, Kobayashi H, Kihara S, Kumada M, Sato K, Inoue T, et al. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem. 2004;279:1304–9.PubMedCrossRef

66.

Shibata R, Ouchi N, Kihara S, Sato K, Funahashi T, Walsh K. Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of amp-activated protein kinase signaling. J Biol Chem. 2004;279:28670–4.PubMedCrossRef

67.

Denzel MS, Hebbard LW, Shostak G, Shapiro L, Cardiff RD, Ranscht B. Adiponectin deficiency limits tumor vascularization in the MMTV-PyV-mT mouse model of mammary cancer. Clin Cancer Res. 2009;15:3256–64.PubMedCrossRef

68.

Landskroner-Eiger S, Qian B, Muise ES, Nawrocki AR, Berger JP, Fine EJ, et al. Proangiogenic contribution of adiponectin toward mammary tumor growth in vivo. Clin Cancer Res. 2009;15:3265–76.PubMedCrossRef

69.

Hebbard LW, Garlatti M, Young LJ, Cardiff RD, Oshima RG, Ranscht B. T-cadherin supports angiogenesis and adiponectin association with the vasculature in a mouse mammary tumor model. Cancer Res. 2008;68:1407–16.PubMedCrossRef

70.

Eren P, Camus S, Matrone G, Ebrahimian TG, Francois D, Tedgui A, et al. Adiponectinemia controls pro-angiogenic cell therapy. Stem Cells. 2009;7:2712–21.CrossRef

71.

Brakenhielm E, Veitonmaki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA. 2004;101:2476–81.PubMedCrossRef

72.

Bora PS, Kaliappan S, Lyzogubov VV, Tytarenko RG, Thotakura S, Viswanathan T, et al. Expression of adiponectin in choroidal tissue and inhibition of laser induced choroidal neovascularization by adiponectin. FEBS Lett. 2007;581:1977–82.PubMedCrossRef

73.

Lyzogubov VV, Tytarenko RG, Thotakura S, Viswanathan T, Bora NS, Bora PS. Inhibition of new vessel growth in mouse model of laser-induced choroidal neovascularization by adiponectin peptide II. Cell Biol Int. 2009;33:765–71.PubMedCrossRef

74.

Man K, Ng KT, Xu A, Cheng Q, Lo CM, Xiao JW, et al. Suppression of liver tumor growth and metastasis by adiponectin in nude mice through inhibition of tumor angiogenesis and downregulation of Rho kinase/IFN-inducible protein 10/matrix metalloproteinase 9 signaling. Clin Cancer Res. 2010;16:967–77.PubMedCrossRef

75.

Kondo M, Shibata R, Miura R, Shimano M, Kondo K, Li P, et al. Caloric restriction stimulates revascularization in response to ischemia via adiponectin-mediated activation of endothelial nitric-oxide synthase. J Biol Chem. 2009;284:1718–24.PubMedCrossRef

76.

Ohashi K, Ouchi N, Sato K, Higuchi A, Ishikawa TO, Herschman HR, et al. Adiponectin promotes revascularization of ischemic muscle through a cyclooxygenase 2-dependent mechanism. Mol Cell Biol. 2009;29:3487–99.PubMedCrossRef

77.

Mao X, Kikani CK, Riojas RA, Langlais P, Wang L, Ramos FJ, et al. APPL1 binds to adiponectin receptors and mediates adiponectin signaling and function. Nat Cell Biol. 2006;8:516–23.PubMedCrossRef

78.

Deepa SS, Dong LQ. APPL1: role in adiponectin signaling and beyond. Am J Physiol Endocrinol Metab. 2009;296:E22–36.PubMedCrossRef

79.

Barb D, Neuwirth A, Mantzoros CS, Balk SP. Adiponectin signals in prostate cancer cells through Akt to activate the mammalian target of rapamycin pathway. Endocr Relat Cancer. 2007;14:995–1005.PubMedCrossRef

80.

Kim KY, Baek A, Hwang JE, Choi YA, Jeong J, Lee MS, et al. Adiponectin-activated AMPK stimulates dephosphorylation of AKT through protein phosphatase 2A activation. Cancer Res. 2009;69:4018–26.PubMedCrossRef

81.

Taliaferro-Smith L, Nagalingam A, Zhong D, Zhou W, Saxena NK, Sharma D. LKB1 is required for adiponectin-mediated modulation of AMPK-S6 K axis and inhibition of migration and invasion of breast cancer cells. Oncogene. 2009;28:2621–33.PubMedCrossRef

82.

Miyazaki T, Bub JD, Uzuki M, Iwamoto Y. Adiponectin activates c-Jun NH2-terminal kinase and inhibits signal transducer and activator of transcription 3. Biochem Biophys Res Commun. 2005;333:79–87.PubMedCrossRef

Titel: Adiponectin and breast cancer
verfasst von: Xiuping Chen
Yitao Wang
Publikationsdatum: 01.12.2011
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 4/2011
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-010-9617-x

Springer Medizin

Adiponectin and breast cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2011

Down-regulation of miR-126 expression in colorectal cancer and its clinical significance

Sustained response following sorafenib therapy in an older adult patient with advanced renal cancer on hemodialysis: a case report

Multidrug resistance strength of the novel multidrug resistance gene HA117: compared with MRP1

Disconnection of chamber and catheter as a complication of central venous catheter type port-a-cath

Association of nuclear factor κB expression with a poor outcome in nasopharyngeal carcinoma

TACE combined with PEI versus TACE alone in the treatment of HCC: a meta-analysis

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie